0001144204-12-059772.txt : 20121211 0001144204-12-059772.hdr.sgml : 20121211 20121106165615 ACCESSION NUMBER: 0001144204-12-059772 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20121106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CANADA STATE: A1 ZIP: M5J 2G2 BUSINESS PHONE: 4163642551 MAIL ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CA STATE: A1 ZIP: M5J 2G2 CORRESP 1 filename1.htm

GENEREX BIOTECHNOLOGY CORPORATION

555 Richmond Street West, Suite 604  
Toronto, Ontario  
Canada  M5V 3B1 Mark A. Fletcher
Telephone:  416.364.2551 President and Chief Executive Officer
Facsimile:   647-547-7104 mfletcher@generex.com

  

Via EDGAR

 

 

November 6, 2012

 

Jeffrey Riedler, Assistant Director

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street N.E. Mail Stop 6010

Washington, D.C. 20549

 

Re:Generex Biotechnology Corporation
Registration Statement on Form S-1
File No. 333-183865

Acceleration Request                       

 

Dear Mr. Riedler:

 

On behalf of Generex Biotechnology Corporation, I hereby request that the Commission grant accelerated effectiveness for the above-referenced Registration Statement at 5:30 p.m. on November 8, 2012 or as soon as reasonably practicable thereafter. The Company understands its obligations under the Securities Act of 1933, as amended, and the rules of the Commission promulgated thereunder, as regards the Registration Statement and distribution of the prospectus.

 

The Company further understands and acknowledges that: should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking action with respect to the filing; the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

 
 

Securities and Exchange Commission

November 6, 2012

Page 2

 

 

Please contact Gary A. Miller, Esq. at 215-851-8472 if you should have any questions regarding this request.

 

Sincerely,

 

GENEREX BIOTECHNOLOGY CORPORATION

 

/s/ Mark A. Fletcher

 

Mark A. Fletcher

President and Chief Executive Officer